TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) (FSE:MLZ) (“MediPharm”) a leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its common shares are now listed on the Frankfurt Stock Exchange (FSE) trading under the ticker symbol “MLZ”. The Company continues to be listed on the Toronto Stock Exchange Venture (TSXV) under the ticker symbol “LABS” and on the OTC in the U.S. under the ticker symbol “MLCPF.”
Listing on the Frankfurt Stock Exchange is an important step in our future growth as we focus on both domestic and international opportunities and also raises MediPharm’s awareness among the global investor community.
Patrick McCutcheon, Chief Executive Officer of MediPharm
As investor interest and momentum in the cannabis industry continues to accelerate, our company is well-positioned to participate in the European and global cannabis markets as they continue to expand, and we receive our EU GMP certification that will allow MediPharm products to be exported across Europe.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-grade cannabis oil and concentrates for advanced derivative products. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream extraction methodologies and purpose-built facilities to deliver pure, safe and precisely-dosed cannabis products to patients and consumers. MediPharm Labs’ private label program is a high margin business for the Company, whereby it opportunistically procures dry cannabis flower and trim from its numerous product supply partners, to produce proprietary cannabis oil concentrate products for resale globally on a private label basis. MediPharm Labs was recently named START-UP OF THE YEAR at the Canadian Cannabis Awards. Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.
